|
 |
CubicinThis page contains recent news articles, when available, and an overview of Cubicin but does not offer medical advice. You should contact your physician with regard to any health issues or concerns.The deal is expected to boost Cubist's portfolio of antibiotics, which includes an injectable drug called Cubicin for treating complicated skin infections. ... San Diego Business Journal Cubist moves to buy Calif. drug maker - Dec 13, 2009 Cubist, a Lexington therapeutics company, already markets an antibiotic, Cubicin, to battle infections caused by the methicillin-resistant Staphylococcus ... Boston Globe Trial date set for Cubist suit against Teva on Cubicin - Dec 13, 2009 Daptomycin is marketed in the US and internationally under the brand name Cubicin (daptomycin for injection) as therapy for serious skin and bloodstream ... pharmabiz.com Cubist, Teva patent suit to head to court - Dec 11, 2009 Cubist officials said earlier this year that they expected net US revenue for Cubicin to be $520 million to $540 million for 2009. Mass High Tech Market Report -- Short Stories (CBST) - Dec 31, 2009 The FDA's decision to not approve represents a major delay for a potentially competing antibiotic to Cubist's CUBICIN. The response also highlights the ... MSN Money Cubist Pharmaceuticals and the New England Patriots Radio Network Recognize ... - Dec 28, 2009 In the US, Cubist markets CUBICIN® (daptomycin for injection), the first antibiotic in a new class of anti-infectives called lipopeptides. ... Earthtimes (press release) Zacks Analyst Blog Highlights: Johnson & Johnson, ViroPharma, Theravance ... - Jan 4, 2010 ...which include ViroPharma's (Nasdaq: VPHM) Vancocin, Theravance's (Nasdaq: THRX) Vibativ, Cubist Pharmaceutical's (Nasdaq: CBST) Cubicin, Pfizer's (NYSE: ... Benzinga Pipeline Setback for JNJ - Analyst Blog - Dec 31, 2009 ...which include ViroPharma's (VPHM) Vancocin, Theravance's (THRX) Vibativ, Cubist Pharmaceutical's (CBST) Cubicin, Pfizer's (PFE) Zyvox and Tygacil. ... Benzinga Today in Globe Business - Dec 14, 2009 Cubist, a Lexington therapeutics company, already markets an antibiotic, Cubicin, to battle infections caused by the methicillin-resistant Staphylococcus ... Boston Globe Cubist Pharmaceuticals, Inc. - Pharmaceuticals & Healthcare - Deals and ... - Dec 29, 2009 The company's lead product, CUBICIN (daptomycin for injection), an intravenous, or IV, antibiotic, developed and launched in the US accounted for majority ... PRMinds (press release) Markets in Brief - Dec 13, 2009 Cubist charges that the Israeli company has infringed on three patents protecting its proprietary antibiotic Cubicin, used to treat dermal and bloodstream ... Ha'aretz Medicines Co. suing Teva, Pliva on additional patent for anti-clotting drug ... - Jan 4, 2010 ...upgraded the stock, saying he believes Cubist will successfully defend the patents on its antibiotic Cubicin, and expects sales will remain strong. ... Gaea Times (blog) Zacks Analyst Blog Highlights: Johnson & Johnson, ViroPharma, Theravance ... - Jan 4, 2010 ...which include ViroPharma's (Nasdaq: VPHM) Vancocin, Theravance's (Nasdaq: THRX) Vibativ, Cubist Pharmaceutical's (Nasdaq: CBST) Cubicin, Pfizer's (NYSE: ... FOXBusiness Deals of the Week: Merry Chrismahanukwanzakah - Dec 18, 2009 ...--Vikas Dandekar and Daniel Poppy Cubist/Calixa: Cubist Pharmaceuticals, the marketer of Cubicin, fulfilled the holiday wishes of investors -- oh, ... The IN VIVO Blog (blog) Cubist calls surge with buyout rumors-11/12/2009 - Nov 12, 2009 On Oct. 16, the biotechnology company reduced the sales forecast for Cubicin, its only product on the market. The shares are climbing today amid unconfirmed ... NASDAQ Cubist Pharmaceuticals Inc. Reports Operating Results (10-Q) - Oct 27, 2009 In the US Cubist markets CUBICIN the first antibiotic in a new class of antiinfectives called lipopeptides. The Cubist product pipeline includes our ... GuruFocus.com About this author: - Nov 5, 2009 CUBICIN is approved in the United States for the treatment of complicated skin and skin structure infections (cSSSI), caused by Staphylococcus aureus (S. ... Seeking Alpha (blog) Biotech, pharma foresee higher costs from House health reform bill - Nov 12, 2009 Cubist makes the drug Cubicin, which is used to treat hospital-borne illnesses. The discounts have, until now, only applied to drugs given in an outpatient ... Mass High Tech The Boston Globe names Cubist to Globe 100's Top Places to Work '09 - Nov 9, 2009 In the US, Cubist markets CUBICIN® (daptomycin for injection), the first antibiotic in a new class of anti-infectives called lipopeptides. ... WELT ONLINE Cubist Pharmaceuticals to Present at Lazard Capital Markets 6th Annual ... - Nov 3, 2009 In the US, Cubist markets CUBICIN® (daptomycin for injection), the first antibiotic in a new class of anti-infectives called lipopeptides. ... Reuters Cubist Pharmaceuticals, Inc. - SWOT Analysis - Aarkstore Enterprise - Oct 29, 2009 The company markets Cubicin (daptomycin for injection), the first antibiotic in a new class of anti-infectives called lipopeptides, in the US. ... PRMinds (press release) www.StockMarketingInc.com: Tuesday's Pick!! GSAE - Green Star Alternative ... - Nov 10, 2009 In the US, Cubist markets CUBICIN(R) (daptomycin for injection), the first antibiotic in a new class of anti-infectives called lipopeptides. ... Trading Markets (press release) Theravance, Inc. Q3 2009 Earnings Call Transcript - Oct 27, 2009 It seems that on a milligram for milligram basis, VIBATIV is charged, or it gets about a 15% to 18% premium over Cubicin. So I just wanted to, ... Seeking Alpha (blog) Cubist Pharmaceuticals, Inc. - Pharmaceuticals & Healthcare - Deals and ... - Nov 9, 2009 The company's lead product, CUBICIN (daptomycin for injection), an intravenous, or IV, antibiotic, developed and launched in the US accounted for majority ... PR-Inside.com (Pressemitteilung) Cubist inks development deal with Hydra - Oct 19, 2009 The deal comes less than a week after Cubist lowered its full-year revenue forecast for its top revenue producer, the antibiotic Cubicin. ... MSN Money DotW: Same As The Old Boss - Oct 23, 2009 The firm is best known for the antibiotic Cubicin (daptomycin), which is on track for half a billion dollars in revenue this year as methicillin-resistant ... The IN VIVO Blog (blog) Experts Back New Cubicin Uses - Mar 7, 2006 By Robert Steyer 03/07/06 - 02:08 PM EST. Shares of Cubist Pharmaceuticals (CBST Quote) were rising Tuesday, a day after a panel of medical experts ... TheStreet.com - TheStreet.com (subscription) AstraZeneca licenses rights for development and sale of Cubicin in... - Dec 4, 2006 LONDON (AFX) - AstraZeneca said it has entered into a licence agreement with NASDAQ-listed Cubist Pharmaceuticals Inc for the development and ... Forbes Cubist posts higher Q3 profit on Cubicin sales - Oct 16, 2008 Oct 16 (Reuters) - Cubist Pharmaceuticals Inc (CBST.O) posted a 38 percent rise in quarterly profit, helped by strong sales of Cubicin, its antibiotic ... Reuters UK Cubist sees antibiotic Cubicin '07 net rev up 35 pct to 45 pct - Apr 18, 2007 April 18 (Reuters) - Cubist Pharmaceuticals Inc. (CBST.O) said it expects 2007 net revenue growth for its antibiotic Cubicin to increase by 35 percent to 45 ... Reuters Cubist shares dip on Cubicin worries - Jan 24, 2008 NEW YORK --Shares of Cubist Pharmaceuticals Inc. sank Thursday after the company issued soft sales guidance for its antibiotic Cubicin and concerns lingered ... Boston Globe Cubist tallies $59M in Cubicin sales - Jan 11, 2005 Cubist Pharmaceuticals says its flagship antibiotic netted nearly $59 million in sales during its first full fiscal year on the market. ... Bizjournals.com Industrial chemical found in Cubicin - Apr 10, 2008 WASHINGTON, April 10 (UPI) -- The US Food and Drug Administration said Cubist Pharmaceuticals is warning that an industrial chemical has been found in the ... United Press International Cubist's Cubicin approved in Canada - Sep 25, 2007 Such an approval is crucial for the Lexington, Mass.-based company (Nasdaq: CBST), which can already sell the drug in the United States, European Union, ... Bizjournals.com Cubist Hit With FDA Setback | Pharmaceuticals News | Print Financial... - Mar 27, 2006 The company has been trying to expand the uses of Cubicin, saying more antibiotics are ... "It is unlikely that Cubicin will obtain a label indication for ... TheStreet.com - TheStreet.com (subscription) Cubicin® receives European approval to expand use to treating two … - Sep 5, 2007 Basel, September 5, 2007 - Cubicin® (daptomycin) has received European Commission approval for expanded use in helping patients suffering from two types of ... webwire.com RPT-UPDATE 1-Cubist sets 2008 Cubicin sales view - Jan 23, 2008 Jan 23 (Reuters) - Cubist Pharmaceuticals Inc (CBST.O) said it sees sales of Cubicin, its antibiotic injection to treat bacterial infections, in the United ... Reuters Cubist Pharmaceuticals Files sNDA to Expand CUBICIN(R) Label for … - Sep 26, 2005 Cubist Pharmaceuticals, Inc. (Nasdaq: CBST) today announced the submission to the US Food & Drug Administration (FDA) of a Supplemental New Drug Application ... RedOrbit Drug stocks gain, Cubist surges on FDA news - MarketWatch - May 26, 2006 ...based biotech group said late Thursday that the FDA has approved its antibiotic Cubicin for the treatment of staph infections in the blood. ... MarketWatch Cubist Q1 profit tops Wall Street estimates - Apr 17, 2008 Cubist gets almost all of its revenue from Cubicin. Revenue for the quarter rose 48 percent to $88.3 million, with Cubicin contributing $87.9 million. ... Reuters Cubist Shares Jump On Rival Trial Data - Aug 23, 2006 ..."We anticipate that Telavancin, if approved, will be used similarly to Cubicin -- primarily after Vancomycin failures -- and will compete directly with ... Forbes CUBICIN Meets Primary Endpoints in Ground-Breaking Staphylococcus … - Jun 27, 2005 OPERATOR: Good afternoon, ladies and gentlemen, and welcome to today's Cubist Pharmaceuticals' conference call. At this time all lines have been placed on a ... Free with registration - Fair Disclosure Wire - AccessMyLibrary.com Superbugs: Where Are the Wonder Drugs? - Oct 29, 2007 Eisenstein knows whereof he speaks; Cubicin, introduced by Cubist in 2003, ... Analysts have projected peak annual sales of $500 million for Cubicin. ... BusinessWeek Cubist shares jump on 2Q profit, raised guidance - Jul 18, 2008 Cubicin, which is approved to treat skin and bloodstream infections, ... Cubicin is used to treat certain vancomycin-resistant strains of skin and other ... Boston Globe … Technical Correction in One of Its US CUBICIN Patents.(Correction... - Sep 12, 2007 In the US, Cubist markets CUBICIN([R])(daptomycin for injection), the first antibiotic in a new class of anti-infectives called lipopeptides. ... Free with registration - Business Wire - AccessMyLibrary.com Big Biotech Bounce - May 26, 2006 Federal health regulators approved Cubicin as a daily treatment for staphylococcus aureus infections in the bloodstream. RBC Capital Markets reiterated an ... Forbes Receiver's suit says banks enabled Bleidt's swindles - Nov 22, 2005 Cubist Pharmaceuticals won an expedited review of its application to market the Cubicin antibiotic for heart and blood infections in the United States, ... Boston Globe … Rights for Development and Commercialization of CUBICIN in Japan... - Mar 22, 2007 Merck will develop and commercialize CUBICIN through its wholly-owned subsidiary, ... CUBICIN will provide a much needed additional therapy for serious ... Free with registration - Business Wire - AccessMyLibrary.com NxStage gets FDA approval for portable dialysis device - Jun 29, 2005 An application seeking priority review and clearance to market Cubicin for the new uses may be ready to file with the Food and Drug Administration by year's ... Boston Globe FDA Issues Approvable Letter for CUBICIN sNDA - Final. - Mar 24, 2006 OPERATOR: Greetings, ladies and gentlemen, and welcome to the Cubist Pharmaceuticals conference call. At this time, all participants in a listen-only mode. ... Free with registration - America's Intelligence Wire - AccessMyLibrary.com CUBICIN Approved for S. aureus Bloodstream Infections in South Korea ... - Aug 1, 2007 Cubist Pharmaceuticals, Inc. (NASDAQ: CBST) today announced that CUBICIN(R) (daptomycin for injection) received approvals in July for S. aureus bacteremia, ... Genetic Engineering News - Genetic Engineering News (press release) Netherlands Corporate News - CUBICIN krijgt groen licht van de ' … - Nov 18, 2005 ...( BW)(CA-CHIRON/CUBIST)(CHIR)(CBST) Positive Opinion For CUBICIN(R) (Daptomycin) Received from European Regulatory Authority; Final EU Approval of ... Netherlands Corporate News - Netherlands Corporate News (persbericht) For Cubist, a tough sell - Aug 18, 2008 Cubist won Food and Drug Administration approval in 2003 to market Cubicin, after several years of research and development. The drug is mainly used to ... Boston Globe Wife of former Cubist exec named in insider trading case - Jan 13, 2005 Lexington-based Cubist (NASDAQ: CBST) announced this week that its flagship antibiotic, Cubicin, netted nearly $59 million in sales during fiscal 2004, ... Boston Business Journal Hospitals Screen for Germs After Medicare Threat - Nov 6, 2007 ...``Just one day is worth about a week of Cubicin.'' Doctors are administering Cubicin earlier in patient treatment rather than risking that infections will ... Bloomberg Analysts' Actions: A Daily Roundup of Street Research - Jul 6, 2006 See strong Cubicin sales. Reiterate Buy rating. Duquesne Light target raised at Jefferies: Jefferies said it is increasing its price target on DQE to $20 ... TheStreet.com - TheStreet.com (subscription) Cubist to sell drug made by AstraZeneca - Jul 3, 2008 One such product is Cubicin, a gram-positive intravenous antibiotic that battles some ... Cubist's 164 sales representatives sell Cubicin to hospitals whose ... Pay-Per-View - Boston Herald - ProQuest Archiver Medinol to seek royalties from Boston Scientific - Sep 27, 2005 Cubist Pharmaceuticals said it filed for US approval of its Cubicin intravenous ... Cubicin works on certain infections regardless of whether they have ... Boston Globe Novartis launches Cubicin for MRSA - Sep 14, 2007 Novartis has launched Cubicin - its novel, first-in-class antibiotic - in the UK, in a new indication to treat the deadly hospital 'superbug' MRSA. ... Pharmafocus Cubist sales rise, boosted by Cubicin - Jan 25, 2005 Cubist Pharmaceuticals Inc. both reduced losses and boosted revenue in its 2004 fiscal year, thanks to sales of its debut antibiotic Cubicin. ... Boston Business Journal Cost of Cash on Illumigen Balance Sheet Adds $1.2 Million Charge to … - Feb 13, 2008 In the US, Cubist markets CUBICIN(R) (daptomycin for injection), ... Cubist and CUBICIN are registered trademarks of Cubist Pharmaceuticals, Inc. ... Lifescience-online Cubicin granted marketing approval in Europe; First-in-class antibioti... - Jan 24, 2006 Chiron Corporation (Nasdaq:CHIR) today announced that the European Commission has granted marketing approval for CUBICIN(R) (daptomycin), a first-in-class ... $4.95 - M2 Presswire - ECNext … Opinion for Expanded Label of CUBICIN Received from European … - Jul 25, 2007 Cubist Pharmaceuticals, Inc. (NASDAQ: CBST) today reported that the Committee for Medicinal Products for Human Use (CHMP), the scientific committee of the ... Genetic Engineering News - Genetic Engineering News (press release) Cubist Q1 profit tops Wall Street estimates - Apr 18, 2008 Cubist gets almost all of its revenue from Cubicin. Revenue for the quarter rose 48 percent to $88.3 million, with Cubicin contributing $87.9 million. ... Orthodontic Products Press Release - Nov 21, 2005 By granting priority review status to CUBICIN, the FDA has established a target date to act on ... Cubist submitted the CUBICIN sNDA on September 26, 2005, ... SNL Interactive - SNL Interactive (subscription) International Approvals: Cubicin and Temodal - Feb 6, 2006 Feb. 6, 2006 — The European Commission has approved daptomycin intravenous infusion for the treatment of complicated skin and soft-tissue infections caused ... Medscape The New England Journal of Medicine Publishes Results of Cubist's … - Aug 16, 2006 CUBICIN is now the only therapy approved for treatment of S. aureus blood ... A safety analysis showed that the incidence of adverse events in CUBICIN and ... Free with registration - Business Wire - AccessMyLibrary.com Pioneering new drug to fight MRSA is given go-ahead in Scotland - Mar 11, 2008 The Scottish Medicines Consortium recommended Cubicin (daptomycin) to treat ... Cubicin is one of only two new classes of antibiotics to be developed in the ... Scotsman Event Brief of Q4 2004 Cubist Pharmaceuticals, Inc. Earnings Conferenc... - Jan 25, 2005 CBST reported net revenues for Cubicin of $21m during 4Q04, an increase of ... Geared up manufacturing for continued sales growth for Cubicin in US and in ... Free with registration - Fair Disclosure Wire - AccessMyLibrary.com Event Brief of Q2 2007 Cubist Pharmaceuticals, Inc. Earnings Conferenc... - Jul 18, 2007 ...s first-in-class IV antibiotic CUBICIN has been used in the treatment of an ... Slightly more than 3.5 years after the launch of CUBICIN, Co. continues to ... Free with registration - Fair Disclosure Wire - AccessMyLibrary.com Press Release: Cubicin granted marketing approval in Europe; First-in... - Jan 24, 2006 Cubicin granted marketing approval in Europe; First-in-class antibiotic approved for treatment of complicated skin and soft-tissue infections; ... Pay-Per-View - M2 Presswire - HighBeam Research … to Purchase 2% Reduction in CUBICIN Royalty Rate from Lilly with … - Mar 3, 2005 LEXINGTON, Mass.--(BUSINESS WIRE)--March 3, 2005--Cubist Pharmaceuticals, Inc. (Nasdaq: CBST) today announced that it entered into definitive agreements to ... SNL Interactive - SNL Interactive (subscription) Targanta Therapeutics seeks FDA approval - Feb 11, 2008 It would compete in the marketplace against drugs including Cubicin, an antibiotic offered by Cubist Pharmaceuticals Inc. (Nasdaq: CBST) in Lexington, ... Bizjournals.com Cubist Pharmaceuticals Reports Third Quarter 2007 Results: Total … - Oct 17, 2007 Total net product revenues for CUBICIN([R]) (daptomycin for injection) ... US net sales of CUBICIN were $75.4 million. Total revenues for the third quarter ... Free with registration - Business Wire - AccessMyLibrary.com Article: Cubicin.(NEW & APPROVED) - Internal Medicine News | … - Jul 15, 2006 Cubicin.(NEW & APPROVED) ... find Internal Medicine News articles. Cubicin (daptomycin for injection, Cubist Pharmaceuticals) A cyclic lipopeptide antibi... Pay-Per-View - Internal Medicine News - HighBeam Research CUBICIN(R) Outcomes Registry and Experience (CORE(R)) Marks … - Oct 21, 2008 Cubist Pharmaceuticals, Inc. (NASDAQ: CBST) continues to leverage its powerful CUBICIN patient registry and experience database known by the acronym CORE. ... RedOrbit … ; Cubist Pharmaceuticals to purchase 2% reduction in Cubicin royalty... - Mar 28, 2005 In exchange for the shares, Cubist's global royalty obligation to Lilly on Cubicin sales will be reduced by 2 percentage points. ... Pay-Per-View - Health & Medicine Week - Factiva, from Dow Jones Cubist Pharmaceuticals Completes Offering of $350 Million in 2.25% … - Jun 6, 2006 In the US, Cubist markets CUBICIN(R) (daptomycin for injection), the first antibiotic in a new class of antiinfectives called lipopeptides. ... Genetic Engineering News - Genetic Engineering News (press release) Targanta asks for EU approval of new antibiotic - Jun 9, 2008 ...in 2009 to compete with Lexington-based Cubist Pharmaceuticals Inc.'s (Nasdaq: CBST) Cubicin and other treatments for antibiotic-resistant infections. ... Mass High Tech Novartis' MRSA drug Cubicin launched in UK. - Sep 24, 2007 Swiss drug major Novartis has launched its new antibiotic Cubicin (daptomycin) in the UK for the treatment of both methicillin-sensitive and resistant ... $4.95 - Pharma Marketletter - ECNext … Announces Significant Sales Milestone; CUBICIN Fastest to Reach... - Jun 9, 2005 CUBICIN has reached this sales milestone faster than any IV antibiotic ever ... CUBICIN has now been used in the treatment of almost 85000 patients with ... $4.95 - Business Wire - ECNext Cubist's chief scientist dies - Oct 3, 2006 Dr. Tally is in many ways the 'father of CUBICIN' the first-in-class IV antibiotic introducted to aid in the fight against 'super bug' in 2003." ... Bizjournals.com South Korea, Taiwan Approve Cubicin for Bloodstream Infections - Aug 2, 2007 Cubist Pharmaceuticals announced that Cubicin received approvals for treating S. aureus bacteremia, including right-sided infective endocarditis (SAB/RIE), ... FDA news - FDA news (subscription) FDA OKs staph infection drug tested at Duke - Aug 17, 2006 Daptomycin, which is marketed by Cubist as Cubicin, was originally approved by FDA officials on Sept. 12, 2003, for use in treating skin infections. ... Bizjournals.com … ; Treatment phase complete in the Cubicin endocarditis/bacteremia... - Apr 3, 2005 2005 APR 3 - (NewsRx.com) -- Cubist Pharmaceuticals, Inc., (CBST) announced all of the enrolled patients have completed the treatment phase of the trial and ... Pay-Per-View - Heart Disease Weekly - Factiva, from Dow Jones Cubicin not tainted but delivery device. - Apr 14, 2008 ReadyMED® is a infusion device used primarily in outpatient settings for administering antiobiotics in the home. ReadyMED® requires little patient or ... Gerson Lehrman Group Q2 2006 Cubist Pharmaceuticals, Inc. Earnings Conference Call - Final. - Jul 19, 2006 On a cumulative basis, Cubicin growth revenues continue to outpace any other IV antibiotic ever introduced in the US Cubicin has now been used in the ... Free with registration - Fair Disclosure Wire - AccessMyLibrary.com Cubist Pharmaceuticals Reports First Quarter 2006 Results; Total … - Apr 19, 2006 CUBICIN continued to show strong revenue growth with $37.9 million of net ... CUBICIN is currently the only once-daily bactericidal antibiotic approved in ... Free with registration - Business Wire - AccessMyLibrary.com Boston Globe, The : ETC. - May 27, 2006 Cubist Pharmaceuticals shares rose 20 percent to $25.55 after the firm's Cubicin antibiotic won US approval to treat stubborn blood infections, an added use ... $2.95 - Boston Globe - NewsBank … ; Cubist Pharmaceuticals to purchase 2% reduction in Cubicin royalty... - Mar 29, 2005 In exchange for the shares, Cubist's global royalty obligation to Lilly on Cubicin sales will be reduced by 2 percentage points. ... Pay-Per-View - Science Letter - Factiva, from Dow Jones Cubist Pharmaceuticals to Announce Third Quarter 2005 Financial … - Oct 19, 2005 CUBICIN is currently the only once-daily bactericidal antibiotic approved ... Cubist and CUBICIN are registered trademarks of Cubist Pharmaceuticals, Inc.; ... businesswire.com Cubist's Antibiotic Cubicin is Tainted: A Mess Not of Their Doing? M ... - Apr 14, 2008 The news that Cubist's Cubicin has been contaminated with 2-mercaptobenzothiazole (MBT) has caused great concern for patients. It appears that the MBT has ... Gerson Lehrman Group … of regulatory review period for purposes of patent extension:... - Jun 14, 2006 The US Food and Drug Administration (FDA) has determined the regulatory review period for Cubicin (daptomycin, US Patent No. ... Pay-Per-View - Federal Register - Factiva, from Dow Jones Cubist Pharmaceuticals Reports Results From HepeX-B(TM) Phase 2 … - Dec 21, 2005 CUBICIN is currently the only once-daily bactericidal antibiotic approved ... Cubist and CUBICIN are registered trademarks of Cubist Pharmaceuticals, Inc.; ... RedOrbit Cubicin.(NEW & APPROVED) - Jul 15, 2006 A cyclic lipopeptide antibiotic--a new antibiotic class--approved for treating patients with Staphylococcus aureus bacteremia, including those with ... Free with registration - Internal Medicine News - AccessMyLibrary.com Cubist Pharmaceuticals Announces Exclusive Option to Acquire Illumigen... - Oct 16, 2007 In the US, Cubist markets CUBICIN([R])(daptomycin for injection), the first antibiotic in a new class of anti-infectives called lipopeptides. ... $4.95 - Business Wire - ECNext CUBICIN(R) Phase 3 Endocarditis/Bacteremia Trial Abstract Accepted... - Sep 9, 2005 LEXINGTON, Mass. -- Cubist Pharmaceuticals, Inc. (Nasdaq: CBST) today announced that the abstract covering efficacy and safety findings from the Phase 3 ... $4.95 - Business Wire - ECNext Strong Ph III data on Cubist's Cubicin.(product development of Cubicin... - Sep 4, 2006 The USA's Cubist Pharmaceuticals has welcomed data published in the August 17 issue of the New England Journal of Medicine from a landmark Phase III study ... Free with registration - Pharma Marketletter - AccessMyLibrary.com Cubicin® (Daptomycin): Treatment of S. Aureus Bacteremia/Endocarditis - Aug 1, 2006 By Erica Tam, Yanina Goykhman, Jessica C. Song, and Paul Hsiao, Erica Tam and Yanina Goykhman are PharmD Candidates, University of the Pacific, Paul Hsiao, ... Pay-Per-View - Infectious Disease Alert - Factiva, from Dow Jones Finance; Cubicin maker reports Q4 and 2004 results; full-year... - Feb 21, 2005 2005 FEB 21 - (NewsRx.com & NewsRx.net) -- Cubist Pharmaceuticals, Inc., (CBST) reported results for the fourth quarter and year ended December 31, 2004. ... Pay-Per-View - Health & Medicine Week - Factiva, from Dow Jones Finance; Cubicin maker reports Q4 and 2004 results; full-year... - Feb 25, 2005 2005 FEB 25 - (NewsRx.com & NewsRx.net) -- Cubist Pharmaceuticals, Inc., (CBST) reported results for the fourth quarter and year ended December 31, 2004. ... Pay-Per-View - Drug Week - Factiva, from Dow Jones Antibiotics; Cubicin maker selects ACS Dobfar as single-source API … - Dec 26, 2005 2005 DEC 26 - (NewsRx.com) -- Cubist Pharmaceuticals, Inc., (CBST) announced that it has selected ACS Dobfar, SpA, as the single source supplier of active ... Pay-Per-View - Anti-Infectives Week - Factiva, from Dow Jones Endocarditis; sNDA filed to expand Cubicin label for S. aureus with … - Oct 28, 2005 2005 OCT 28 - (NewsRx.com) -- Cubist Pharmaceuticals, Inc., (CBST) announced submission to the US Food & Drug Administration (FDA) of a supplemental new ... Pay-Per-View - Drug Week - Factiva, from Dow Jones Event Brief of Q3 2007 Cubist Pharmaceuticals, Inc. Earnings Conferenc... - Oct 17, 2007 CUBICIN IV antibiotic now has been used in treatment of more than 400000 ... Driven by CUBICIN opportunity ahead of CBST but also positions it well to ... Free with registration - Fair Disclosure Wire - AccessMyLibrary.com Cubist Pharmaceuticals Announces Posting of Briefing Documents for … - Mar 3, 2006 The CUBICIN sNDA, which has been granted Priority Review by the FDA with a PDUFA ... The sponsor document includes background on CUBICIN, a review of the ... RedOrbit Endocarditis; sNDA filed to expand Cubicin label for S. aureus with … - Oct 25, 2005 2005 OCT 25 - (NewsRx.com) -- Cubist Pharmaceuticals, Inc., (CBST) announced submission to the US Food & Drug Administration (FDA) of a supplemental new ... Pay-Per-View - Life Science Weekly - Factiva, from Dow Jones Q & A Cubist Eyes Big Payoff With Bacteria-Fighting Agent - Jan 9, 2006 Since then, Cubist has funded studies of Cubicin in resistant infections of the ... The data showed that Cubicin was more effective than vancomycin in all ... Pay-Per-View - Investor's Business Daily - Factiva, from Dow Jones … Infections; Companies seek EU regulatory approval to market Cubicin... - Jan 7, 2005 The filing includes safety data from two pivotal phase III clinical trials conducted by Cubist that examined the safety and efficacy of Cubicin in the ... Pay-Per-View - Drug Week - Factiva, from Dow Jones … Infections; Companies seek EU regulatory approval to market Cubicin... - Jan 3, 2005 The filing includes safety data from two pivotal phase III clinical trials conducted by Cubist that examined the safety and efficacy of Cubicin in the ... Pay-Per-View - Health & Medicine Week - Factiva, from Dow Jones Article: Cubicin, Wellbutrin XL.(Drug overview) - Family Practice... - Jul 15, 2006 Cubicin, Wellbutrin XL.(Drug overview) ... find Family Practice News articles. Cubicin (daptomycin for injection, Cubist Pharmaceuticals) A cyclic ... Pay-Per-View - Family Practice News - HighBeam Research Q2 2005 Cubist Pharmaceuticals, Inc. Earnings Conference Call - Final. - Jul 20, 2005 Early in June, we announced that Cubicin had passed $100 million in cumulative net ... In the second quarter alone, Cubicin revenues grew 23% versus Q1, ... Free with registration - Fair Disclosure Wire - AccessMyLibrary.com International Approvals: Atripla, Cubicin, Galvus - Oct 22, 2007 October 22, 2007 — Health Canada has approved efavirenz plus emtricitabine/tenofovir disoproxil fumarate tablets for use alone or with other antiretroviral ... Medscape Cubist Pharmaceuticals Announces Fourth Quarter 2006 US Net Product … - Jan 8, 2007 Mike Bonney, President and CEO of Cubist said, "CUBICIN has experienced year-over-year ... In the US, Cubist markets CUBICIN(R) (daptomycin for injection), ... Genetic Engineering News - Genetic Engineering News (press release) Gov. Patrick cuts ribbon to open drug company's new labs - Sep 29, 2008 Cubist's largest product is cubicin, an antibiotic that treats methicillin-resistant Staphylococcus aureus (MRSA), or treatment-resistant staph infections. ... MetroWest Daily News … $10.25M up front for Asian right to Cubicin.(Cubist Pharmaceuticals... - Dec 18, 2006 Pharmaceuticals for the commercialization of the latter's antibiotic Cubicin (daptomycin for injection) in China and certain other Asian countries, ... Free with registration - Pharma Marketletter - AccessMyLibrary.com Cubist warns FDA of impurity in Cubicin - Aug 18, 2008 Cubist Pharmaceuticals has informed the FDA that Cubicin, its antibiotic treatment for skin and blood infections, was contaminated with an industrial ... SmartBrief Cubist Pharma (CBST) Announces FDA Okay for Expanded CUBICIN … - May 26, 2006 After the close of trading Thursday, Cubist Pharmaceuticals, Inc. (Nasdaq: CBST) announced that the FDA has approved the supplemental new drug application ... StreetInsider.com - StreetInsider.com (subscription) New Licence for Cubicin(R) (daptomycin), the First in a Novel Class... - Sep 12, 2007 The launch of daptomycin for the treatment of both methicillin-sensitive and resistant Staphylococcus aureus (MSSA and MRSA) bloodstream infections ... Free with registration - PR Newswire - AccessMyLibrary.com New indication.(approval of cubicin for treating bloodstream infection... - Jun 26, 2006 Cubist Pharmaceuticals Inc. has won approval to promote Cubicin for treating bloodstream infections and related heart infections. ... Free with registration - Chain Drug Review - AccessMyLibrary.com International Approvals: Cubicin, BeneFIX, Aricept - Sep 17, 2007 September 17, 2007 — The European Commission has approved daptomycin intravenous infusion for the treatment of right-sided infective endocarditis and ... Medscape Cubist Pharmaceuticals Announces the End of Patient Dosing in HepeX- … - Aug 9, 2005 CUBICIN is currently the only once-daily bactericidal antibiotic approved ... Cubist and CUBICIN are registered trademarks of Cubist Pharmaceuticals, Inc.; ... $4.95 - Business Wire - ECNext Finance; Company reports Q4 Cubicin revenues of $21.0M, year-end net ... - Feb 7, 2005 2005 FEB 7 - (NewsRx.com & NewsRx.net) -- Cubist Pharmaceuticals, Inc., (CBST) announced $21.0 million in net revenue (unaudited) for its flagship ... Pay-Per-View - Anti-Infectives Week - Factiva, from Dow Jones Finance; Company reports Q4 Cubicin revenues of $21.0M, year-end net ... - Feb 11, 2005 2005 FEB 11 - (NewsRx.com & NewsRx.net) -- Cubist Pharmaceuticals, Inc., (CBST) announced $21.0 million in net revenue (unaudited) for its flagship ... Pay-Per-View - Drug Week - Factiva, from Dow Jones Event Brief of Q1 2005 Cubist Pharmaceuticals, Inc. Earnings Conferenc... - Apr 20, 2005 CBST reported roughly $21m in net Cubicin revenue in 1Q05, with total net ... Cubicin: 1. Sales trend since launch continues to validate the significant ... Free with registration - Fair Disclosure Wire - AccessMyLibrary.com FDA Issues Approvable Letter for CUBICIN sNDA - Research and Markets … - Mar 29, 2006 The Cubist Pharmaceuticals, Inc. (CBST) Corporate Conference Call took place on 24-Mar-06 7:00pm ET CBST is disappointed that it has not been able to reach ... Free with registration - Europe Intelligence Wire - AccessMyLibrary.com FDA OKs expanded label for Cubist's Cubicin. - Jun 5, 2006 FDA OKs expanded label for Cubist's Cubicin. The US Food and Drug Administration has approved Cubist Pharmaceuticals' supplemental new drug application for ... $9.94 - Pharma Marketletter - Alacra Store |
|
Health Home | Conditions | Cancer | Medications | Surgery | Vaccines The Cancer News Network
COPYRIGHT 2009 CANCERNEWSNETWORK | Privacy |